293 related articles for article (PubMed ID: 15044616)
21. Comparative agonist/antagonist responses in mutant human C5a receptors define the ligand binding site.
Higginbottom A; Cain SA; Woodruff TM; Proctor LM; Madala PK; Tyndall JD; Taylor SM; Fairlie DP; Monk PN
J Biol Chem; 2005 May; 280(18):17831-40. PubMed ID: 15661745
[TBL] [Abstract][Full Text] [Related]
22. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats.
Arumugam TV; Woodruff TM; Stocks SZ; Proctor LM; Pollitt S; Shiels IA; Reid RC; Fairlie DP; Taylor SM
J Hepatol; 2004 Jun; 40(6):934-41. PubMed ID: 15158333
[TBL] [Abstract][Full Text] [Related]
23. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.
Woodruff TM; Strachan AJ; Sanderson SD; Monk PN; Wong AK; Fairlie DP; Taylor SM
Inflammation; 2001 Jun; 25(3):171-7. PubMed ID: 11403208
[TBL] [Abstract][Full Text] [Related]
24. Synthetic small-molecule complement inhibitors.
Holland MC; Morikis D; Lambris JD
Curr Opin Investig Drugs; 2004 Nov; 5(11):1164-73. PubMed ID: 15573867
[TBL] [Abstract][Full Text] [Related]
25. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies.
Lee H; Zahra D; Vogelzang A; Newton R; Thatcher J; Quan A; So T; Zwirner J; Koentgen F; Padkjaer SB; Mackay F; Whitfeld PL; Mackay CR
Nat Biotechnol; 2006 Oct; 24(10):1279-84. PubMed ID: 16980974
[TBL] [Abstract][Full Text] [Related]
26. Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat.
Short AJ; Paczkowski NJ; Vogen SM; Sanderson SD; Taylor SM
Br J Pharmacol; 1999 Oct; 128(3):511-4. PubMed ID: 10516626
[TBL] [Abstract][Full Text] [Related]
27. C5a structural requirements for neutrophil receptor interaction.
Mollison KW; Fey TA; Krause RA; Miller L; Edalji RP; Conway RG; Mandecki W; Shallcross MA; Kawai M; Or YS
Agents Actions Suppl; 1991; 35():17-21. PubMed ID: 1664187
[TBL] [Abstract][Full Text] [Related]
28. Identification of a new class of small molecule C5a receptor antagonists.
Chen JJ; Cole DC; Ciszewski G; Crouse K; Ellingboe JW; Nowak P; Tawa GJ; Berstein G; Li W
Bioorg Med Chem Lett; 2010 Jan; 20(2):662-4. PubMed ID: 20004096
[TBL] [Abstract][Full Text] [Related]
29. Expression of an epitope tagged human C5a receptor and antibody-mediated immobilization of detergent-solubilized receptor for drug discovery screening.
Sloan DD; Barrett RW; Tate EH; England BP
Protein Expr Purif; 1997 Oct; 11(1):119-24. PubMed ID: 9325147
[TBL] [Abstract][Full Text] [Related]
30. The pharmacophore of the human C5a anaphylatoxin.
Toth MJ; Huwyler L; Boyar WC; Braunwalder AF; Yarwood D; Hadala J; Haston WO; Sills MA; Seligmann B; Galakatos N
Protein Sci; 1994 Aug; 3(8):1159-68. PubMed ID: 7987211
[TBL] [Abstract][Full Text] [Related]
31. Derivation of ligands for the complement C3a receptor from the C-terminus of C5a.
Halai R; Bellows-Peterson ML; Branchett W; Smadbeck J; Kieslich CA; Croker DE; Cooper MA; Morikis D; Woodruff TM; Floudas CA; Monk PN
Eur J Pharmacol; 2014 Dec; 745():176-81. PubMed ID: 25446428
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.
Strachan AJ; Shiels IA; Reid RC; Fairlie DP; Taylor SM
Br J Pharmacol; 2001 Dec; 134(8):1778-86. PubMed ID: 11739255
[TBL] [Abstract][Full Text] [Related]
33. Protection of innate immunity by C5aR antagonist in septic mice.
Huber-Lang MS; Riedeman NC; Sarma JV; Younkin EM; McGuire SR; Laudes IJ; Lu KT; Guo RF; Neff TA; Padgaonkar VA; Lambris JD; Spruce L; Mastellos D; Zetoune FS; Ward PA
FASEB J; 2002 Oct; 16(12):1567-74. PubMed ID: 12374779
[TBL] [Abstract][Full Text] [Related]
34. Relationship of C5a receptor modulation to the functional responsiveness of human polymorphonuclear leukocytes to C5a.
Van Epps DE; Simpson SJ; Johnson R
J Immunol; 1993 Jan; 150(1):246-52. PubMed ID: 8417126
[TBL] [Abstract][Full Text] [Related]
35. A convergent solution-phase synthesis of the macrocycle Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a potent new antiinflammatory drug.
Reid RC; Abbenante G; Taylor SM; Fairlie DP
J Org Chem; 2003 May; 68(11):4464-71. PubMed ID: 12762752
[TBL] [Abstract][Full Text] [Related]
36. A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptides.
Sun H; Greeley DN; Chu XJ; Cheung A; Danho W; Swistok J; Wang Y; Zhao C; Chen L; Fry DC
Bioorg Med Chem; 2004 May; 12(10):2671-7. PubMed ID: 15110848
[TBL] [Abstract][Full Text] [Related]
37. Complement C5A regulates prolabor mediators in human placenta.
Lappas M; Woodruff TM; Taylor SM; Permezel M
Biol Reprod; 2012 Jun; 86(6):190. PubMed ID: 22441801
[TBL] [Abstract][Full Text] [Related]
38. Discovery of small molecule human C5a receptor antagonists.
Sanganee HJ; Baxter A; Barber S; Brown AJ; Grice D; Hunt F; King S; Laughton D; Pairaudeau G; Thong B; Weaver R; Unitt J
Bioorg Med Chem Lett; 2009 Feb; 19(4):1143-7. PubMed ID: 19171482
[TBL] [Abstract][Full Text] [Related]
39. Biologic activity of synthetic analogues of C5a anaphylatoxin.
Ember JA; Sanderson SD; Taylor SM; Kawahara M; Hugli TE
J Immunol; 1992 May; 148(10):3165-73. PubMed ID: 1578141
[TBL] [Abstract][Full Text] [Related]
40. Transdermal pharmacology of small molecule cyclic C5a antagonists.
Proctor LM; Woodruff TM; Sharma P; Shiels IA; Taylor SM
Adv Exp Med Biol; 2006; 586():329-45. PubMed ID: 16893082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
